logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
M

María Jesús Rubio

Reina Sofía University Hospital
H指数:20
被引数:1,744

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: 1-Year Follow-Up After Final Analysis of the ENGOT-en9/LEAP-001 Phase 3 Trial

一线仑伐替尼联合帕博利珠单抗与化疗治疗晚期子宫内膜癌：ENGOT-en9/LEAP-001 III期试验最终分析后的1年随访

International Journal of Gynecological Cancer
IF4.7
2025-11-110
PRE
Christian Marth; Richard G. Moore; Mariusz Bidziński; Vanda Salutari; Özden Altundağ; Maria Jesús Rubio; Tally Levy; Alison Stillie; Christof Vulsteke; Ralf Witteler; Kazuya Ariyoshi; Xiaohua Wu; Sophia Frentzas; André Mattar; Brian M. Slomovitz; Stephanie Lheureux; Xiaojun Chen; Kosei Hasegawa; Manuel Magallanes; Chel Hun Choi
DOMENICA: dostarlimab versus chemotherapy alone in first-line MMR-deficient advanced endometrial cancer patients

DOMENICA：dostarlimab与单药化疗相比，用于一线治疗MMR缺乏的晚期子宫内膜癌患者

FUTURE ONCOLOGY
IF2.6
2025-05-050
PRE
Cherifi, Francois; Ray-Coquard, Isabelle; Rubio, Maria Jesus; Paoletti, Xavier; Lorusso, Domenica; Choi, Chel Hun; Hasegawa, Kosei; Tan, David Shao Peng; Hudson, Emma; Davis, Alison; Tognon, Germana; Lheureux, Stephanie; Vardar Key, Mehmet Ali; Kurtz, Jean Emmanuel; Alexandre, Jerome; Joly, Florence
Retrospective multicenter study of elderly patients with platinum-sensitive relapsed ovarian cancer treated with trabectedin and pegylated liposomal doxorubicin (pld) in a real-world setting: a geico study

在真实世界中，对接受trabectedin和聚乙二醇化脂质体阿霉素 (pld) 治疗的铂敏感复发性卵巢癌老年患者的回顾性多中心研究: geico研究

BMC CANCER
IF3.4
2024-07-050
OAAI
Rubio, Maria Jesus; Manzano, Aranzazu; de Sande, Luis Miguel; Estevez-Garcia, Purificacion; Gordon, Maria del Mar; de Prado, Diego Soto; de Aranguiz, Blanca Hernando Fernandez; Guerra-Alia, Eva M.; Carbo-Bague, Anna; Romero, Ignacio; Corbellas, Miguel; Gonzalez-Haba, Alba; Robles-Barraza, Carlos E.; Martinez-Garcia, Jeronimo; Gonzalez-Martin, Antonio
Olaparib in combination with pegylated liposomal doxorubicin for platinum-resistant ovarian cancer regardless of BRCA status: a GEICO phase II trial (ROLANDO study)

奥拉帕尼联合聚乙二醇化脂质体阿霉素治疗铂耐药卵巢癌，无论BRCA状态如何: GEICO II期试验 (ROLANDO研究)

ESMO OPEN
IF8.3
2021-08-0119
OAAI
Perez-Fidalgo, J. A.; Cortes, A.; Guerra, E.; Garcia, Y.; Iglesias, M.; Sarmiento, U. Bohn; Garcia, E. Calvo; Sanchez, L. Manso; Santaballa, A.; Oaknin, A.; Redondo, A.; Rubio, M. J.; Gonzalez-Martin, A.
A randomised double-blind placebo-controlled phase II trial of palbociclib combined with letrozole (L) in patients (pts) with oestrogen receptor-positive (ER plus ) advanced/recurrent endometrial cancer (EC): NSGO-PALEO / ENGOT-EN3 trial
ANNALS OF ONCOLOGY
IF65.4
2020-09-0149
OAAI
Mirza, M. R.; Bjorge, L.; Marme, F.; Christensen, R. DePont; Gil-Martin, M.; Auranen, A.; Ataseven, B.; Rubio, M. J.; Salutari, V.; Lund, B.; Runnebaum, I.; Redondo, A.; Lindemann, K.; Trillsch, F.; Barretina Ginesta, M. P.; Roed, H.; Lohndorf, J.; Nyvang, G-B.; Sehouli, J.
Randomized, open-label, phase II trial of dostarlimab (TSR-042), as maintenance therapy for patients with high-risk locally advanced cervical cancer after chemo-radiation: ATOMICC study
ANNALS OF ONCOLOGY
IF65.4
2020-09-015
OAAI
Oaknin, A.; Iglesias, M.; Alarcon, J. D.; Villacampa Javierre, G.; Gaba Garcia, L.; Santaballa, A.; Manso, L. M.; Romero, I.; Barretina Ginesta, M. P.; Churruca, C.; Garcia, Y.; Sanchez, A. B.; Marquina, G.; Pardo, B.; Redondo, A.; Rubio, M. J.; Gonzalez Martin, A.
Preoperative olaparib in early-stage endometrial cancer (EC): A phase 0, window of opportunity trial to evaluate the PARP inhibition effect, targeting cell cycle-related proteins (POLEN study)
ANNALS OF ONCOLOGY
IF65.4
2016-10-010
OAAI
Romero, I.; Rubio, M. J.; Serrano, R.; Medina, M.; Minig, L.; Casado, A.; Coronado, P.; Martinez, S.; Orbegoso, C.; Fuste, P.; Guerra Alia, E. M.; Sanchez-Martinez, M. C.; Rubio, D.; Santacana, M.; Ruiz, M.; Llombart-Cussac, A.; Matias-Guiu, X.; Poveda, A. M.
Poor concordance between CA-125 and RECIST at the time of disease progression in patients with platinum-resistant ovarian cancer: analysis of the AURELIA trial

铂类耐药卵巢癌患者疾病进展时CA-125与RECIST一致性差: AURELIA试验分析

ANNALS OF ONCOLOGY
IF65.4
2016-08-0134
OAAI
Lindemann, K.; Kristensen, G.; Mirza, M. R.; Davies, L.; Hilpert, F.; Romero, I.; Ayhan, A.; Burges, A.; Rubio, M. J.; Raspagliesi, F.; Huizing, M.; Creemers, G. -J.; Lykka, M.; Lee, C. K.; Gebski, V.; Pujade-Lauraine, E.

研究方向

暂未获取到该数据
A
Antonio González-Martı́n
H 指数:67论文数:662被引数:3.3万
I
Ignacio Romero
H 指数:31论文数:235被引数:5,431
A
Andrés Redondo
H 指数:45论文数:382被引数:1.5万
A
Ana Oaknin
H 指数:71论文数:715被引数:3.6万
J
José Alejandro Pérez Fidalgo
H 指数:40论文数:392被引数:6,978
Y
Yolanda García García
H 指数:25论文数:142被引数:3,246
M
Maria-Pilar Barretina-Ginesta
H 指数:16论文数:91被引数:1,511
L
Luís Manso
H 指数:39论文数:451被引数:8,433
A
Ana Santaballa
H 指数:25论文数:200被引数:1,752
M
María Iglesias
H 指数:13论文数:62被引数:749